Compounded semaglutide became widely available during FDA-declared shortages as a lower-cost alternative to Ozempic and Wegovy. At its peak, dozens of telehealth platforms were selling it for a fraction of the branded price. The regulatory situation has since shifted considerably. Understanding what compounded semaglutide is — and where things stand now — matters before making any decisions about it.
What compounded medications are
Compounding pharmacies have always existed. They mix medications customized for individual patients — adjusting doses, changing formulations (liquid instead of pill), or making products for people with allergies to specific inactive ingredients.
FDA-approved drugs are normally off-limits for compounding — manufacturers have exclusive rights, and compounded versions would undercut that. The exception is shortage. When an FDA-approved drug is on the official shortage list, compounding pharmacies are legally permitted to produce equivalent versions to meet patient demand.
Semaglutide (Ozempic and Wegovy) went on the FDA shortage list in 2022 and remained there through most of 2023 and 2024. During that window, compounding pharmacies produced semaglutide for injection, often sourcing the active pharmaceutical ingredient from approved suppliers.
The key differences from branded versions
Compounded semaglutide is not identical to Ozempic or Wegovy. The FDA does not test or approve compounded products. Quality control depends entirely on the compounding pharmacy’s practices, which vary significantly.
The active molecule — semaglutide — can be the same. What’s different is everything else: the inactive ingredients, the stabilizers, the delivery device, and the potency testing. Some compounding pharmacies added ingredients like B12 or L-carnitine to their formulations without clinical evidence for added benefit.
A wave of FDA warnings in 2023 and 2024 cited specific compounding pharmacies for quality problems, including incorrect dosing, sterility failures, and undeclared ingredients.
The regulatory change
In early 2025, the FDA removed semaglutide from the shortage list for Ozempic (the lower-dose, diabetes-approved version). With the shortage designation removed, compounding of semaglutide under the shortage exception became legally impermissible for 503A compounding pharmacies.
503B outsourcing facilities — which operate under stricter FDA oversight — retain somewhat broader compounding authority, but their primary market is hospitals and clinics, not direct-to-consumer telehealth.
The practical result: as of mid-2025, most telehealth platforms offering compounded semaglutide have either discontinued those offerings or are operating in a legally contested gray area. Some platforms pivoted to compounded tirzepatide, whose shortage status has been more variable.
What this means if you’ve been using compounded semaglutide
If you started on compounded semaglutide and it was working, switching to branded Wegovy or Ozempic is the medically equivalent path — same active ingredient, FDA-approved manufacturing. The barrier is cost.
Options worth exploring: manufacturer savings programs (NovoCare patient assistance for qualifying income levels), state pharmaceutical assistance programs, and asking your prescriber whether a diabetes diagnosis qualifies you for Ozempic coverage rather than Wegovy.
The situation continues to evolve. The legal battles between compounding interests and pharmaceutical manufacturers were ongoing as of mid-2026. Staying informed through your prescribing telehealth provider about current status is the most reliable approach.
This content is for educational purposes only and is not medical advice. Consult your healthcare provider before making changes to your diet, supplements, or medications.
